Selkirk Pharma vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Contract Development & Manufacturing Organization (CDMO) — Sterile Injectables
Selkirk Pharma is a US-based CDMO specializing in aseptic fill/finish for sterile injectable drug products; raised $82M+ total; operates a 115,000 sq ft GMP facility in Spokane, WA; blueprinted a $90M expansion factory;
About
Selkirk Pharma is a contract development and manufacturing organization (CDMO) founded in 2018 by fill/finish industry veterans and headquartered in Spokane, Washington. The company was purpose-built to address the domestic shortage of aseptic fill/finish manufacturing capacity for sterile injectable drug products — a segment critical to biologics, small molecules, and parenteral medicines. Its 115,000-square-foot GMP facility at the Pacific Northwest Technology Park operates with advanced isolator technology from SKAN, Bausch and Strobel VarioSys dose-filling systems, and single-use systems designed to meet both US FDA and EU Annex 1 compliance standards.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.